The promise of AI in MedTech is undeniable, but a major regulatory storm is brewing in the European Union. A new, complex dual-compliance framework now requires AI-driven medical devices to satisfy both the rigorous Medical Device Regulation (MDR) and the brand-new EU AI Act. This episode of MedTech Global Insights dives deep into what this means for manufacturers, from startups to global enterprises.

We explore the immense challenge of navigating two separate sets of demanding requirements. Consider a company with a market-ready AI diagnostic tool, holding a complete MDR technical file. They suddenly find their product classified as "high-risk" under the AI Act, forcing them into a costly and time-consuming redesign of their entire compliance, data governance, and risk management strategy, putting their European launch in jeopardy.

What You'll Learn:

- Why is the EU's new AI Act creating a dual compliance headache for MedTech innovators?

- What does it mean to navigate both the MDR and the AI Act simultaneously?

- How does the AI Act's "high-risk" classification impact your regulatory strategy?

- Is your current Quality Management System prepared for AI-specific demands?

- What are the new rules for post-market surveillance of AI algorithms?

- Why are cross-functional teams of engineers and regulatory experts now essential?

- What critical questions must you ask about your AI's training data to ensure compliance?

- How can you avoid common pitfalls that lead to costly market launch delays?

Contact us at [email protected] or visit https://pureglobal.com/. Explore our FREE AI tools and medical device database at https://pureglobal.ai/.